What's new

Referral: Mysimba, naltrexone,bupropion Article 20 procedures European Commission final decision, 27/03/2025, 22/05/2025, 26/05/2025

Referral: Mysimba, naltrexone,bupropion Article 20 procedures European Commission final decision, 27/03/2025, 22/05/2025, 26/05/2025

May 26, 2025 - 16:15
 0
Referral: Mysimba, naltrexone,bupropion Article 20 procedures European Commission final decision, 27/03/2025, 22/05/2025, 26/05/2025
Referral: Mysimba, naltrexone,bupropion Article 20 procedures European Commission final decision, 27/03/2025, 22/05/2025, 26/05/2025
Read More

Tags:

Previous Article

Referral: Oxbryta, Voxelotor Article 20 procedures Under evaluation, 26/05/2025

Next Article

NATO Secretary General meets the Prime Minister of Iceland

Related Posts

EMA workshop on primary efficacy endpoints for antivirals and monoclonal antibodies intended for the treatment of COVID-19 and influenza, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 5 June 2025, 13:00 (CEST) to 6 June 2025, 17:00 (CEST)

EMA workshop on primary efficacy endpoints for antivira...

May 13, 2025  0

Human medicines European public assessment report (EPAR): Lyfnua, gefapixant, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

May 14, 2025  0

Human medicines European public assessment report (EPAR): Levetiracetam Hospira, levetiracetam, Date of authorisation: 07/01/2014, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR...

May 12, 2025  0